Nitto Avecia is a contract development and manufacturing organization (CDMO) specializing in the development and production of oligonucleotide therapeutics. With over 30 years of experience, the company has manufactured more than 1,200 different oligonucleotide sequences and supports programs from preclinical through commercial supply. Nitto Avecia operates FDA-inspected, GMP-compliant facilities in Massachusetts and Ohio, and is part of the Nitto Group, sharing a vision of 'Creating Wonders.'
cGMP per USFDA 21 CFR Parts 210 and 211
Compliance program
ICH Q7 Good Manufacturing Guidance for Active Pharmaceutical Ingredients
Compliance program
EU Current Good Manufacturing Practice for Active Pharmaceutical Ingredients
Compliance program
ICH Q8 Pharmaceutical Development
Compliance program
ICH Q9 Quality Risk Management
Compliance program
ICH Q10 Pharmaceutical Quality System
Compliance program
ICH Q11 Development and Manufacture of Drug Substance
Compliance program
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
Compliance program
EUGMP
Quality certification
Olon USAFounded in 1986 and acquired by Olon SpA in 2017, Olon USA is a contract research, development, and manufacturing partner focused on small-molecule drugs and other chemical-based industries. Its single 25-acre Concord, Ohio site brings together 160,000 square feet of laboratory and manufacturing space, with services spanning development through scale-up and production. The company reports that 71% of its chemists hold advanced degrees and that its quality system has supported audits by more than 200 clients and the U.S. FDA.CONCORD, OH
Minaris Advanced TherapiesBorn from the 2025 combination of Minaris Regenerative Medicine and WuXi Advanced Therapies, Minaris Advanced Therapies is a global contract development and manufacturing organization serving developers of cell and gene therapies. Its identity rests on a long technical lineage: more than 25 years in therapy manufacturing, over 40 years in advanced testing, and a history that includes producing the first GMP cell therapy lot in the United States in 2004. The company now supports programs from early development through commercial supply across facilities in North America, Europe and Asia.PHILADELPHIA, PA
LOTTE BIOLOGICSLOTTE BIOLOGICS is a global CDMO focused on helping pharmaceutical companies develop and manufacture biologic therapies. Its work spans development through clinical and commercial production, supported by GMP facilities in Syracuse, New York, and a planned Songdo Bio Campus in South Korea.EAST SYRACUSE, NY
Forge BiologicsFounded by gene therapy developers for developers, Forge Biologics is a Columbus, Ohio-based contract development and manufacturing organization focused on AAV gene therapy development and production. Its 200,000-plus-square-foot Hearth facility has 20 cGMP suites and supports programs from research through clinical and commercial manufacturing. Forge is part of Ajinomoto Bio-Pharma Services and brings more than 450 experts to its work with gene therapy developers.GROVE CITY, OH